Genrix (shanghai) Biopharmaceutical Co., Ltd.

This study is testing whether a new injection called GR1803 works better than the current standard treatment for multiple myeloma that has returned or stopped responding to previous therapies. It will involve about 358 adults whose cancer has progressed after 1-3 prior treatments…

This early-stage trial is testing a new injection called GR1803 in people with systemic lupus erythematosus (SLE), a serious autoimmune disease. The main goal is to see if the treatment is safe and if it can help control the disease. The study will enroll 44 participants who have…

This study is testing whether an experimental injection called GR1802, when added to a person's usual allergy medicines, can better control the sneezing, runny nose, and itchy eyes caused by seasonal allergies. It will involve 150 adults whose symptoms are not well-controlled by …

This is an early safety study testing a new injection called GR2303 in healthy volunteers. Researchers will give 64 participants either the drug or a placebo (inactive substance) to see how the body handles it and check for side effects. The main goal is to understand if GR2303 i…